CA2439288C - Method for protecting cells and tissues from ionizing radiation toxicity with .alpha.,.beta. unsaturated aryl sulfones - Google Patents

Method for protecting cells and tissues from ionizing radiation toxicity with .alpha.,.beta. unsaturated aryl sulfones Download PDF

Info

Publication number
CA2439288C
CA2439288C CA2439288A CA2439288A CA2439288C CA 2439288 C CA2439288 C CA 2439288C CA 2439288 A CA2439288 A CA 2439288A CA 2439288 A CA2439288 A CA 2439288A CA 2439288 C CA2439288 C CA 2439288C
Authority
CA
Canada
Prior art keywords
ionizing radiation
radiation
exposure
use according
radioprotective compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2439288A
Other languages
English (en)
French (fr)
Other versions
CA2439288A1 (en
Inventor
Premkumar E. Reddy
Ramana M.V. Reddy
Stephen C. Cosenza
Lawrence Helson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Traws Pharma Inc
Original Assignee
Onconova Therapeutics Inc
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconova Therapeutics Inc, Temple Univ School of Medicine filed Critical Onconova Therapeutics Inc
Publication of CA2439288A1 publication Critical patent/CA2439288A1/en
Application granted granted Critical
Publication of CA2439288C publication Critical patent/CA2439288C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2439288A 2001-02-28 2002-02-28 Method for protecting cells and tissues from ionizing radiation toxicity with .alpha.,.beta. unsaturated aryl sulfones Expired - Lifetime CA2439288C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28
US60/271,990 2001-02-28
PCT/US2002/006107 WO2002069892A2 (en) 2001-02-28 2002-02-28 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES

Publications (2)

Publication Number Publication Date
CA2439288A1 CA2439288A1 (en) 2002-09-12
CA2439288C true CA2439288C (en) 2011-08-09

Family

ID=23037934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2439288A Expired - Lifetime CA2439288C (en) 2001-02-28 2002-02-28 Method for protecting cells and tissues from ionizing radiation toxicity with .alpha.,.beta. unsaturated aryl sulfones

Country Status (10)

Country Link
US (1) US6667346B2 (enExample)
EP (1) EP1370253B8 (enExample)
JP (1) JP4302986B2 (enExample)
KR (1) KR100850331B1 (enExample)
AT (1) ATE406881T1 (enExample)
AU (1) AU2002305942B2 (enExample)
CA (1) CA2439288C (enExample)
DE (1) DE60228692D1 (enExample)
IL (2) IL157541A0 (enExample)
WO (1) WO2002069892A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296677A1 (en) 2000-10-05 2002-04-15 Temple University - Of The Commonwealth System Of Higher Education Substituted (e)-styryl benzylsulfones for treating proliferative disorders
US7161031B2 (en) * 2002-02-28 2007-01-09 Temple University - Of The Commonwealth System Of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
MXPA04008356A (es) * 2002-02-28 2005-09-12 Univ Temple (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas con un grupo amino y en la posicion 4 para tratar trastornos poliferativos.
HUE032523T2 (en) * 2003-11-14 2017-09-28 Temple Univ - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for the treatment of proliferative disorders
JP2007512378A (ja) * 2003-11-26 2007-05-17 アークル インコーポレイテッド 放射線障害から保護するためのβ−ラパコンの使用
EP1740530B8 (en) 2004-03-16 2017-03-01 Temple University - Of The Commonwealth System of Higher Education Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders
EP1773310B9 (en) 2004-06-24 2012-04-25 Temple University - Of The Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
WO2006010152A2 (en) * 2004-07-19 2006-01-26 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
KR101427105B1 (ko) * 2005-01-05 2014-08-07 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 약-내성 증식성 질병의 치료
US8143453B2 (en) * 2005-02-25 2012-03-27 Temple University—Of the Commonwealth System of Higher Education Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
AU2006275822B2 (en) * 2005-07-29 2012-02-02 Onconova Therapeutics, Inc. Formulation of radioprotective alpha, beta unsaturated aryl sulfones
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
US20090247624A1 (en) * 2006-07-28 2009-10-01 Onconova Therapeutics Inc. Formulations of radioprotective alpha beta unsaturated aryl sulfones
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
CA2663375A1 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
EP2091527B1 (en) * 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
CA2738909A1 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
JP5734869B2 (ja) * 2008-12-16 2015-06-17 オンコノバ・セラピューティックス・インコーポレーテッド ヒトにおける細胞毒性物質の有害作用に対する治療レジメンの有効性を決定する方法
EP2429566B1 (en) 2009-05-13 2016-01-06 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
MX336278B (es) * 2010-03-24 2016-01-13 Onconova Therapeutics Inc Composiciones y metodos para la prevencion y el tratamiento de heridas.
SI2552199T1 (sl) 2010-03-26 2015-10-30 Onconova Therapeutics, Inc. Izboljšana stabilna vodna formulacija (e)-4-karboksistiril-4-klorobenzil sulfona
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
JP2013545758A (ja) 2010-11-17 2013-12-26 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護
ES2863538T3 (es) 2012-09-20 2021-10-11 Univ Temple Derivados de alquil diarilo sustituidos, métodos de preparación y usos
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
CA2906166C (en) 2013-03-15 2023-03-14 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
AU2015204239B2 (en) * 2014-01-06 2018-04-19 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
US20150297608A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US12410124B2 (en) 2019-07-18 2025-09-09 Huaxiashengsheng Pharmaceutical Beijing Co., Ltd. Carbamate-substituted styryl sulfone compounds, preparation method and use thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100579355B1 (ko) 1997-10-03 2006-05-12 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 스티릴 설폰 항암제
US6201154B1 (en) 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
EP1173160B1 (en) 1999-04-02 2005-06-22 Temple University of the Commonwealth System of Higher Education (e)-styryl sulfone anticancer agents
JP2002541101A (ja) * 1999-04-02 2002-12-03 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション スチリルスルホン抗癌剤
WO2001026645A1 (en) * 1999-10-12 2001-04-19 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
WO2001076592A1 (en) * 2000-04-06 2001-10-18 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
JP4171656B2 (ja) * 2001-02-28 2008-10-22 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途

Also Published As

Publication number Publication date
CA2439288A1 (en) 2002-09-12
JP4302986B2 (ja) 2009-07-29
US6667346B2 (en) 2003-12-23
WO2002069892A3 (en) 2002-11-07
KR100850331B1 (ko) 2008-08-04
EP1370253B8 (en) 2008-11-26
AU2002305942B2 (en) 2006-10-26
EP1370253A2 (en) 2003-12-17
ATE406881T1 (de) 2008-09-15
EP1370253B1 (en) 2008-09-03
WO2002069892A2 (en) 2002-09-12
KR20030086596A (ko) 2003-11-10
IL157541A0 (en) 2004-03-28
US20030060505A1 (en) 2003-03-27
EP1370253A4 (en) 2005-08-17
IL157541A (en) 2010-05-31
JP2004525908A (ja) 2004-08-26
DE60228692D1 (de) 2008-10-16

Similar Documents

Publication Publication Date Title
US6667346B2 (en) Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones
AU2002305942A1 (en) Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
US6646009B2 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
Luo et al. The molecular mechanisms of acetaminophen-induced hepatotoxicity and its potential therapeutic targets
AU2002306604A1 (en) N-(Aryl)-2-arylethenesulfonamides and therapeutic uses thereof
CA2656273A1 (en) Prevention of nuclear, solar, and other radiation-induced tissue damage
WO2005044181A2 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EP1539675B1 (en) Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
WO2005065074A2 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
Stewart et al. Radioprotection of mouse skin by WR-2721 in single and fractionated treatments
Carnes et al. In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis
JP5196787B2 (ja) 増殖性疾患を治療するためのα，β−不飽和スルホキシド
AU780844B2 (en) Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
Ghossein et al. The treatment of locally advanced carcinoma of the colon and rectum by a surgical procedure and radiotherapy postoperatively.
CN110354133A (zh) 四氢生物蝶呤的应用及药物
Groves et al. Saving normal tissues–a goal for the ages
JP2007512378A (ja) 放射線障害から保護するためのβ−ラパコンの使用
Miyatake et al. ACT-02 BORON NEUTRONS CAPTURE THERAPY FOR RECURRENT HIGH-GRADE MENINGIOMAS, FROM REACTOR TO ACCELERATOR
CN110354257A (zh) 鸟苷三磷酸环化水解酶1的应用及药物
Moncrief Experimental and Theoretical Aspects of Severe Trauma
Tawfik et al. Examining Rapamycin's Role in Cancer Prevention: Insights from Dr. Mikhail Blagosklonny's Research

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220228